Trestle Bio and Humacyte Form Research Collaboration

March 11, 2025—Trestle Biotherapeutics, Inc. recently announced a research collaboration with Humacyte, Inc. Trestle Bio is a preclinical-stage company developing implantable bioengineered kidney tissues for patients with end-stage renal disease (ESRD).

Biotronik Partners With Egg Medical to Market EggNest Radiation Protection Systems

February 19, 2025—Biotronik announced it is partnering with Egg Medical, Inc. to cosell Egg Medical’s EggNest radiation protection systems for health care workers in the United States.

Transit Scientific’s XO Constrain 2.2 F Angioplasty Platform Cleared by FDA

June 26, 2024—Transit Scientific announced that its XO Constrain 2.2 F angioplasty platform received FDA clearance to modify calcified plaque and fibrous lesions in the peripheral vasculature.

GE HealthCare and MediView Launch OmnifyXR Augmented Reality Interventional Suite

June 20, 2024—GE HealthCare and MediView XR Inc. announced the first installation of the OmnifyXR interventional suite.

Getinge’s Advanta V12 Covered Stent System Receives EU MDR Certification

April 11, 2024—Sweden-based Getinge announced the European Union Medical Device Regulation (EU MDR) certification of its Advanta V12 covered stent system.

HistoSonics Commences CAIN Trial of Histotripsy Platform to Treat Renal Tumors

April 5, 2023—HistoSonics recently announced that the first kidney patient has been treated using the company’s histotripsy platform.

Medtronic’s Symplicity Spyral RDN System Demonstrates Clinical Benefits in SPYRAL HTN-ON MED Trial

November 7, 2022—Medtronic announced the 6-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial.

Gore Acquires InnAVasc Medical

August 12, 2022—Gore & Associates announced the acquisition of InnAVasc Medical, Inc., a privately-held medical technology company focused on care for patients with end-stage renal disease who utilize graft circuits for dialysis treatment.

Transit Scientific Reports Early Clinical Experience With XO Score Sheath Platform

June 30, 2022—Transit Scientific announced findings from the early commercial experience with the XO Score sheath platform that showed successful outcomes on multiple fistula and graft cases using the XO Score devices along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons.

Medtronic’s Symplicity Spyral RDN System Studied at 3 Years in SPYRAL HTN-ON MED Trial

April 4, 2022—Medtronic announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which demonstrated that patients who were prescribed antihypertensive medications and treated with the company’s Symplicity Spyral renal denervation (RDN) system continued to show durable, clinically significant blood pressure reductions through 3 years.

Nipro’s Cronus HP PTA Balloon Catheter Introduced in United States

March 30, 2022—Nipro Medical Corporation announced the introduction of the second-generation Cronus HP high-pressure percutaneous transluminal angioplasty (PTA) balloon catheter in the United States.

Oscor Recalls Models of Destino Twist and Guidestar Steerable Guiding Sheaths

January 11, 2022—Oscor Inc. announced it is voluntarily recalling 14 lots of Destino Twist 14 F, model DST1405525, and the Guidestar 14 F, model D141103, down to the user level.

Medtronic’s In.Pact AV and In.Pact Admiral Devices Evaluated in Subset Data Presented at CIRSE

September 29, 2021—Medtronic announced the presentation of new subset data for its In.Pact AV paclitaxel drug-coated balloon (DCB) for arteriovenous (AV) access maintenance and for its In.Pact Admiral paclitaxel-coated percutaneous transluminal angioplasty (PTA) catheter.

Fist Assist’s FA-1 Compression Device Studied in FACT for Superficial Arm Vein Dilation

August 4, 2021—Fist Assist Devices, LLC, announced completion of the nonsignificant risk trial, Fist Assist Clinical Trial (FACT).

Risk of Renal Failure Shown to Increase After Lytic Therapy for Acute DVT

July 26, 2021—The Society for Vascular Surgery (SVS) announced the publication of findings from a large single-center retrospective study demonstrating that the risk of acute kidney injury (AKI) after pharmacomechanical thrombolysis (PMT) for lower extremity deep vein thrombosis (DVT) is as high as 22%.

Pulnovo Medical Completes Enrollment in Trial of Pulmonary Artery Denervation to Treat Hypertension

June 28, 2021—Pulnovo Medical announced that the PADN-CFDA randomized controlled trial of the company’s pulmonary artery denervation (PADN) device to treat hypertension has completed patient enrollment.